Search results
Results from the WOW.Com Content Network
Results of the trial issued in April 2021 show the homegrown COVID-19 vaccine is safe. [14] According to the trial results, people injected with 25mcg dose got the highest index with more than 90% at 14 days after the second shot and 42 days since the first doses.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
The COVID-19 High-Performance Computing Consortium also aims to predict the spread of disease, model possible vaccines, and study thousands of chemical compounds to develop a COVID-19 vaccine or therapy. [37] [38] As of May 2020, the Consortium has used up 437 petaFLOPS of computing power.
In October 2024, the CHMP gave a positive opinion to update the composition of Nuvaxovid, a vaccine to target the SARS-CoV-2 JN.1 variant of the virus that causes COVID-19 following the recommendations issued by EMA's Emergency Task Force to update COVID-19 vaccines for the 2024/2025 vaccination campaign. [75]
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
In December, studies, some of which using large nationwide datasets from either Israel and Denmark, found that vaccine effectiveness of multiple common two-dosed COVID-19 vaccines is substantially lower against the Omicron variant than for other common variants including the Delta variant, and that a new (often a third) dose – a booster dose ...
In contrast to other mRNA COVID-19 vaccines, such as those by Pfizer-BioNTech and Moderna, this vaccine primarily targets the SARS-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. [4] It is approved for Phase III trials in China, [5] Mexico, [6] Indonesia, [7] and Nepal. [8]
A universal coronavirus vaccine, also known as a pan-coronavirus vaccine, is a theoretical coronavirus vaccine that would be effective against all coronavirus strains. A universal vaccine would provide protection against coronavirus strains that have caused disease in humans, such as SARS-CoV-2 (including all its variants), while also providing ...